Our test can help identify patients that will benefit from therapy intensification
Our test outperforms standard clinical tools that prognosticate outcomes
Our AI biomarkers can prognosticate long-term outcomes and predict therapeutic benefit to enable localized prostate cancer therapy personalization.
Five phase III randomized trials were used to develop and validate prognostic and predictive AI biomarkers.
Artera’s multimodal AI was developed with over 16,000 digitized histopathology slides from over 5,000 patients.
Osama Mohamad, MD
University of California San Francisco
Dr. Mohamad discusses the development and validation of a multimodal artificial intelligence (MMAI)-derived prognostic biomarker in localized prostate cancer. The biomarker was shown to consistently outperform the standard NCCN risk stratification tool.
ASCO GU 2022 link
Daniel Spratt, MD
Case Western Reserve University
Dr. Spratt discusses how an MMAI-derived predictive biomarker is able to discriminate between patients with intermediate-risk prostate cancer who would or would not benefit from adding ADT to RT.
ASCO GU 2022 link
Mack Roach, MD, FASTRO, FASCO
University of California San Francisco
Dr. Roach discusses how the performance of the multimodal artificial intelligence (MMAI)-derived prognostic biomarker is comparable between African American and non-African American subgroups.
ASCO 2022 link